Clinical Efficacy of Topical Glucocorticoid Preparations and Other Types of Dermatics in Inflammatory Diseases, Particularly in Atopic Dermatitis

2015 ◽  
pp. 157-169 ◽  
Author(s):  
Roland Niedner ◽  
Erwin Sch�pf
Keyword(s):  
Atopic Dermatitis ◽  
Clinical Efficacy ◽  
Inflammatory Diseases

The Clinical Efficacy of a Multi-Lamellar Emulsion Containing Pseudoceramide in Childhood Atopic Dermatitis: An Open Crossover Study

2003 ◽  
Vol 15 (4) ◽  
pp. 133 ◽  
Author(s):  
Eun Ju Lee ◽  
Ki Beom Suhr ◽  
Jeung Hoon Lee ◽  
Jang Kyu Park ◽  
Chun Yu Jin ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Crossover Study ◽  
Clinical Efficacy ◽  
Open Crossover

scholarly journals Fermented Morinda citrifolia (Noni) Alleviates DNCB-Induced Atopic Dermatitis in NC/Nga Mice through Modulating Immune Balance and Skin Barrier Function

Nutrients ◽  
2020 ◽  
Vol 12 (1) ◽  
pp. 249 ◽  
Author(s):  
Kim ◽  
Seong ◽  
Choung
Keyword(s):  
Atopic Dermatitis ◽  
Barrier Function ◽  
Molecular Mechanisms ◽  
Inflammatory Diseases ◽  
Skin Barrier ◽  
Inflammatory Cells ◽  
Skin Lesions ◽  
Morinda Citrifolia ◽  
Skin Barrier Function ◽  
Immune Balance

Morinda citrifolia, a fruit generally known as “Noni”, has been traditionally used in parts of East Asia to relieve inflammatory diseases. Although several studies using noni have been reported, the effect of fermented Morinda citrifolia (F.NONI) on atopic dermatitis (AD) has not been investigated. Thus, we aimed to investigate the improving effect of F.NONI treatment on AD-like skin lesions and elucidate molecular mechanisms. F.NONI was prepared by the fermentation of noni fruit with probiotics and then extracted. F.NONI was orally administrated to NC/Nga mice to evaluate its therapeutic effect on 2,4-dinitrochlorobenzene (DNCB)-induced AD. Oral administration of F.NONI significantly alleviated AD lesions and symptoms such as dermatitis scores, ear thickness, scratching behavior, epidermal thickness, and infiltration of inflammatory cells (e.g., mast cells and eosinophils). In addition, F.NONI treatment reduced the levels of histamine, IgE and IgG1/IgG2a ratio, thymus and activation regulated chemokine (TARC), and thymic stromal lymphopoietin (TSLP) in serum and beneficially modulated the expressions of Th1, Th2, Th17, and Th22-mediated cytokines in lesioned skin and splenocytes. Furthermore, the expressions of the skin barrier-related proteins including filaggrin (FLG), loricrin (LOR), involucrin (IVL), zonula occludens-1 (ZO-1), and occludin (OCC) were restored by F.NONI treatment. Taken together, these results suggest that F.NONI could be a therapeutic agent to attenuate AD-like skin lesions through modulating the immune balance and skin barrier function.

scholarly journals Chrysin Inhibits NF-κB-Dependent CCL5 Transcription by Targeting IκB Kinase in the Atopic Dermatitis-Like Inflammatory Microenvironment

2020 ◽  
Vol 21 (19) ◽  
pp. 7348
Author(s):  
Hyunjin Yeo ◽  
Young Han Lee ◽  
Dongsoo Koh ◽  
Yoongho Lim ◽  
Soon Young Shin
Keyword(s):  
Atopic Dermatitis ◽  
Inflammatory Responses ◽  
Inflammatory Diseases ◽  
Binding Pocket ◽  
Skin Lesions ◽  
Transcriptional Level ◽  
Inflammatory Microenvironment ◽  
Design And Synthesis ◽  
Iκb Kinase ◽  
Chemokine Ligand

Chrysin (5,7-dihydroxyflavone) is a natural polyphenolic compound that induces an anti-inflammatory response. In this study, we investigated the molecular mechanism underlying the chrysin-induced suppression of C-C motif chemokine ligand 5 (CCL5) gene expression in atopic dermatitis (AD)-like inflammatory microenvironment. We showed that chrysin inhibited CCL5 expression at the transcriptional level through the suppression of nuclear factor kappa B (NF-κB) in the inflammatory environment. Chrysin could bind to the ATP-binding pocket of the inhibitor of κB (IκB) kinase (IKK) and, subsequently, prevent IκB degradation and NF-κB activation. The clinical efficacy of chrysin in targeting IKK was evaluated in 2,4-dinitrochlorobenzene-induced skin lesions in BALB/c mice. Our results suggested that chrysin prevented CCL5 expression by targeting IKK to reduce the infiltration of mast cells to the inflammatory sites and at least partially attenuate the inflammatory responses. These findings suggested that chrysin might be useful as a platform for the design and synthesis of small-molecule IKK-targeting drugs for the treatment of chronic inflammatory diseases, such as AD.

Clinical efficacy of neural therapy for the treatment of atopic dermatitis in dogs

2008 ◽  
Vol 56 (4) ◽  
pp. 459-469 ◽  
Author(s):  
Adriana Bravo-Monsalvo ◽  
Juan Vázquez-Chagoyán ◽  
Lilia Gutiérrez ◽  
Héctor Sumano
Keyword(s):  
Atopic Dermatitis ◽  
Clinical Efficacy ◽  
Severity Index ◽  
Control Group ◽  
Matched Pairs ◽  
Neural Therapy ◽  
Canine Atopic Dermatitis ◽  
Dermatological Condition ◽  
Before And After ◽  
History Of

The aim of this trial was to assess the clinical efficacy of neural therapy (NT) when treating canine atopic dermatitis. Eighteen dogs (no control group), with at least a 12-month history of having nonseasonal atopic dermatitis, were included. No medication with either glucocorticoids or cyclosporin was allowed during the trial. One set of NT was given by injecting an intravenous dose of 0.1 mg/kg of a 0.7% procaine solution, followed by 10 to 25 intradermal injections of the same solution in a volume of 0.1–0.3 mL per site. Dogs were given 6–13 sets of NT during the therapy. The dermatological condition of each patient was evaluated before and after the treatment using two scales: the pruritus visual analogue scale (PVAS) and the canine atopic dermatitis extent and severity index (CADESI). The reduction of pruritus was statistically significant using a Wilcoxon matched-pairs signed-ranks test (P < 0.001). No adverse side effects were observed. NT seems to be an effective alternative to control signs related to canine atopic dermatitis.

Sign in / Sign up

Export Citation Format

Share Document